**Core Concept**
Multiple myeloma is a type of blood cancer characterized by the proliferation of malignant plasma cells in the bone marrow. The prognosis of multiple myeloma is determined by various factors, including age, performance status, renal function, and the presence of high-risk cytogenetic abnormalities.

**Why the Correct Answer is Right**
The correct answer to this question requires an understanding of the poor prognostic factors in multiple myeloma. In general, a high serum lactate dehydrogenase (LDH) level is a marker of high tumor burden and metabolic activity, which is associated with a poorer prognosis. **Option A** is correct because a high serum LDH level is indeed a poor prognostic factor in multiple myeloma.

**Why Each Wrong Option is Incorrect**
* **Option B:** Elevated serum calcium levels are actually a common finding in multiple myeloma due to bone destruction and parathyroid hormone-related protein (PTHrP) production. While hypercalcemia can cause symptoms, it is not a poor prognostic factor.
* **Option C:** Anemia is a common feature of multiple myeloma due to bone marrow infiltration by malignant plasma cells. However, anemia itself is not a poor prognostic factor, and treatment can often improve hemoglobin levels.
* **Option D:** This option is incomplete.

**Clinical Pearl / High-Yield Fact**
In multiple myeloma, a high serum LDH level is often associated with a high International Staging System (ISS) stage and a shorter overall survival. This correlation is an important consideration when evaluating patients with multiple myeloma.

**Correct Answer: A. Elevated serum lactate dehydrogenase (LDH) level is a poor prognostic factor in multiple myeloma.**